Hormonal health
What the NHS 10-Year Health Plan means for women and where it “falls short”
The government’s 10-year plan for the NHS promises bold transformation, with a move towards digital innovation, and more focus on prevention over treatment, but does it go far enough to address the UK’s gender health gap?
Health Secretary Wes Streeting has revealed his vision for the UK’s public healthcare system, promising to transform the NHS over the next decade, in the government’s Fit for the Future report.
From a renewed focus on maternity care, to ambitions to eliminate cervical cancer by 2040, the government says its 10-year plan will play a fundamental role in delivering its commitment to women’s health “never again being ignored”.
Currently, the UK has the largest gender health gap in the G20, with the average woman spending nearly a quarter of her life in poor health compared to a fifth for men.
Yet while the plan has been described as a “strong foundation”, crucial details about how its promises will be delivered are yet to be published, and some say the lack of specific action to address the gender health gap mean it may “fall short” for women.
Community, prevention and digitisation— what the government has promised
The NHS 10 year plan is underpinned by three key pillars; a move from hospital to community, sickness to prevention and from analogue to digital.
A focus on prevention, rather than sickness, promises to deliver better access to screening, and allow better use of health data to enable more predictive and pre-emptive care.
Plans to increase uptake of HPV vaccinations aim to help the NHS reach its ambitious target of eliminating cervical cancer by 2040. Meanwhile, universal newborn genomic testing and an introduction to polygenic risk scoring will be used to identify potential risks to child and maternal health early and help predict susceptibility to diseases.
The government has also committed to a national independent investigation into maternity and neonatal services, setting out plans for the establishment of a national maternity and neonatal taskforce, chaired by the Secretary of State, as well as a national action plan co-produced with bereaved families.
Placing more focus on neighbourhood health centres, rather than hospital treatment, will enable more people to access health services closer to home, according to the proposals, while an increased focus on the digitalisation of the NHS aims to make services faster, more convenient, and more personalised.
All patients will gain access to a single, digital health record, and the NHS app will be expanded allowing patients to book appointments, manage long-term conditions, reproductive health and medications, and coordinate care for children or elderly family members.
My Children, a digital alternative to what has been known for decades in maternity care as the ‘red book’ also aims to make it easier to manage children’s healthcare and medical records.
Speaking following the publication of the plan on Thursday 3 July, Streeting described this as a “meaningful advancement”, giving parents “practical tools when they need them most”.
“This isn’t just about convenience… It’s about recognising the realities of modern parenthood and removing unnecessary barriers to good healthcare,” he said.
“From offering timely, advice about feeding and weaning in those first months to providing guidance about adolescent mental health years later, this digital companion adapts to your family’s changing needs.”
Where the plan “falls short” on women’s health
The plan’s proposals for maternity care have been welcomed by the Royal College of Obstetricians and Gynaecologists (RCOG), with many women not receiving the “personalised, high-quality care they deserve”.
However, president, Professor Ranee Thakar, has suggested it lacks clarity on how it will address many of the the issues contributing to the gender health gap.
“While the plan lays strong foundations, it falls short in pledging to eliminate the gender health gap that is costing women years of life and good health,” Prof Thakar said in statement on Thursday.
“Today’s plan must mark a move away from treating women’s health as a collection of niche issues towards offering women excellent, joined-up care across their life course, with investment in the women’s health workforce, Femtech and research.”
Despite the fact that one in three women in the UK will suffer from a reproductive or gynaecological problem, less than 2.5 per cent of publicly funded research is dedicated solely to reproductive health.
Thakar added: “A huge opportunity may be missed without a clear focus on delivering better for women. We would like to see the Women’s Health Strategy for England reset quickly, to work alongside the 10-Year Plan in driving improvements in women’s health access, experiences and outcomes, particularly for minority ethnic women and those in the most socially deprived areas.”
The Women’s Health Strategy, developed and published in 2022, promised to address the inequalities in the health and care system, by providing better care for menstrual and gynaecological conditions, expanding women’s health hubs, improving maternity care and accelerating research into women’s health.
Some have been critical of the roll out of the strategy, accusing the former Conservative government of using it as a “short-term vote winner” and failing to fund it properly. A total of £25m was allocated to fund one-stop-shop women’s health hubs across the country for two years, compared to £240m which was spent on the Rwanda deportation scheme.
The role of women’s health hubs
The RCOG has called for the acceleration of women’s health hubs, which its believes could play a “crucial role” in establishing the neighbourhood care model which Streeting has promised in his 10-year plan.
Hubs bring healthcare services together, making the referral process easier and allowing women to see see different specialists, therapists and diagnostic teams under one roof, which can be beneficial for those managing complex symptoms or chronic health issues.
However according to Dr Nikki Kanani, a GP specialising in women’s health and a former director of primary care for NHS England, many are still in the pilot stage and services are stretched due to a lack of healthcare professionals trained in women’s health.
“What we need to do is follow through on the commitment of the strategy, to understand what good looks like and invest in scaling that,” she tells Femtech World.
“We need to treat hubs as a core part of the system, not just a side project,” she tells Femtech World.
“We need to understand what good looks like and invest in scaling that. That needs to be clearly set out with nationally-protected funding and ICB accountability. We need to upscale across primary care, we need roles that reflect the breadth of the knowledge that’s needed, and we need protected time for clinicians to work in these spaces.”
Dr Kanani also believes hubs also need to move beyond focusing on reproductive issues to other areas of healthcare where women are traditonally “dismissed” and “deprioritised”, such as cardiovascular care and mental health services.
Alongside this, incentivised targets for gender and ethnicity gaps in diagnosis, referrals and outcomes, as well as system-wide women’s health leads, could be practical next steps to ensure women’s health is prioritised across the NHS, Dr Kanani says.
Increased investment in private innovators
The government has promised to embrace technologies such as AI, genomics, wearables and robotics, to improve clinical outcomes and reduce clinician workload, which could see a shift towards more public-private partnerships in the NHS and more investment in private innovators.
Dr Kanani says this would be “welcome”, but innovators seeking NHS partnerships, especially in the women’s health space, will need to consider factors such as regulator requirements, responsible data-gathering and the practicalities of training clinicians.
“Any femtech company innovating a point of care solution should be thinking not just of their tool, but also how their tool improves decision-making, documentation and communication, she says.
“We can roll out thousands of tools, but frontline clinicians are understandably time-poor. Part of your job as a responsible innovator, is to say ‘here is my solution, let’s train you and make sure it’s easy to use and deploy’.”
Equity needs more than strategy
The promises of the 10-year plan are bold and ambitious, but how effective it will be— especially for women— remains to be seen.
A planned chapter explaining how the proposed changes would be delivered was not published alongside the rest of the plan on Thursday, and is now expected later this year.
Dr Kanani says how the plan is delivered will be crucial in determining how far it goes to improve women’s healthcare.
“There are some important steps in the 10-year plan, but health equity for women, particularly those from minoritised, marginalised and underserved communities, won’t be achieved through strategy alone. We need a really deep, system-wide culture shift,” she says.
“Equity needs more than just the narrative of equal access, it needs tailored design. Care models, research, workforce, all need to be actively built around these women and communities.”
Dr Kanani adds: “It could be transformational for women, but only if it’s designed intentionally around the realities of women’s lives.”
Menopause
IBSA UK launches non-hormonal injectable for menopause symptoms
IBSA UK has introduced Hyaluxelle, a non-hormonal menopause treatment for vulvo-vaginal atrophy, easing vaginal dryness and pain during intercourse.
Hyaluxelle is given as deep intradermal injections to the vulvar vestibule, the area at the vaginal opening, in two sessions one month apart, followed by clinical reassessment.
IBSA UK is the UK subsidiary of Swiss pharmaceutical company IBSA.
Vulvo-vaginal atrophy is a key feature of genitourinary syndrome of menopause, a long-term condition caused by low oestrogen that affects genital, urinary and sexual health.
At least half of post-menopausal women are affected, yet many do not seek help, often assuming symptoms are part of ageing.
The condition stems from thinning and drying of vaginal and vulval tissues linked to low oestrogen, leading to symptoms such as dryness, discomfort, altered pH and pain during intercourse.
Hyaluxelle combines high and low molecular weight hyaluronic acid, a moisture-retaining substance found naturally in the body.
The company says this creates a lower-viscosity injection at what it describes as the highest concentration available in the UK, supporting tissue hydration, firmness and elasticity.
The formulation is said to rehydrate the vulvar vestibule and create conditions for restoring tissue structure through collagen and elastin production.
Clinical studies indicate Hyaluxelle improves several vulvo-vaginal symptoms, including reductions in discomfort and pain during intercourse.
Studies also report gains in sexual function domains and a positive trend in some aspects of health-related quality of life.
Histological analyses suggest increased epithelial thickness, enhanced tissue regeneration and reduced inflammatory infiltration after the procedure. In studies, the treatment was well tolerated with no reported major complications.
Joanna, a 59-year-old woman living with severe symptoms, described the personal impact of delayed diagnosis.
She said: “I lived for years with pain, UTIs, cystitis and a loss of sensation, but every visit to my GP, even a female GP, was treated as a bladder issue.
“Nobody suggested it might be linked to the menopause or joined the dots, and none of the treatments I was given helped. Without the right information or support, I became desperate for answers.
“The symptoms affected everything, what I wore, how I exercised, how I slept, but the hardest part was the impact on intimacy with my husband.
“I withdrew from our relationship because I was scared sex would hurt, and the loss of closeness was devastating, and I no longer felt like myself.
“Women deserve clear explanations and real options when their symptoms are not getting better.”
IBSA says Hyaluxelle offers clinicians an option for women whose symptoms persist despite first-line therapies, or for those who cannot receive or choose not to receive hormonal treatments.
Menopause
Flo Health and Mayo Clinic publish global perimenopause awareness study
The US ranks sixth for perimenopause knowledge, behind the UK, Ireland, Canada, Australia and the Netherlands, research by the Mayo Clinic and period tracker Flo has revealed.
Perimenopause is the transition leading up to a woman’s last menstrual cycle and includes the 12 months afterwards, after which menopause is established as hormone levels change.
It typically happens in the mid-40s and lasts an average of six years, though symptoms may start in the 30s.
The study surveyed more than 17,000 women aged 18 and over across 158 countries about their knowledge of perimenopause symptoms.
The US ranked sixth overall, despite growing public discussion of menopause linked to celebrity advocacy and new workplace policies.
Participants most often recognised common symptoms such as hot flushes (71 per cent), sleep problems (68 per cent) and weight gain (65 per cent).
Broader symptoms, including fatigue, irritability and digestive changes, were far less likely to be identified as part of the perimenopause transition.
Among women aged 35 and over who reported being in perimenopause, the five most common symptoms were physical and mental exhaustion (95 per cent), fatigue (93 per cent), irritability (91 per cent), sleep problems (89 per cent) and depressive mood (88 per cent).
Dr Anna Klepchukova, chief medical officer at Flo, said: “We need to normalise conversations around perimenopause and menopause, so women feel empowered to have honest conversations with their doctors and other support systems.
“This study demonstrates a prolonged commitment from both Flo Health and Mayo Clinic in helping women better understand their bodies and advocating for their health through perimenopause, and every other phase of their health journeys, through medically-backed insights and advice.”
International differences
Perimenopause knowledge scores were highest in higher-income countries such as the UK, Ireland and Australia.
Lower scores emerged in Nigeria, France and parts of Latin America.
Digestive issues ranked among the top three reported symptoms in Nigeria, South Africa, India, France, Ireland and several Latin American countries, while mood symptoms such as depressive mood and anxiety ranked among the top three in Germany, Spain, Venezuela, the Netherlands and India.
Dr Mary Hedges, principal investigator at Mayo Clinic, said: “There is a mismatch in knowledge and expectations of perimenopause and actual symptoms experienced during perimenopause.
Many women in perimenopause may not yet be experiencing hot flashes, and are more likely to be experiencing the cognitive and physical symptoms of fatigue, exhaustion, mood, sleep, or even digestive changes.
“The findings from this study illustrate the need to advance perimenopause research and education, so that we can equip both patients and healthcare clinicians with the knowledge and skills needed to address symptoms and improve the quality of care we provide to women.”
The survey ran from 6 December 2024 to 16 May 2025.
Wellness
Study offers hope to women suffering menopause hot flushes and night sweats
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight3 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight1 week agoParents sue IVF clinic after delivering someone else’s baby
-
Insight2 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Events4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026







